Semaglutide Distribution Flexibility: EMA Approves Room Temperature Delivery for Wegovy®

The European Medicines Agency (EMA) has granted an important update to the product information for Wegovy (semaglutide), introducing semaglutide distribution flexibility that allows controlled-temperature delivery at up to 30°C for up to 48 hours during the final leg from pharmacies to patients. This makes Wegovy the first GLP-1 receptor agonist approved for weight management in Europe with such semaglutide distribution flexibility.

Easing Cold-Chain Demands

The partial relaxation of strict cold-chain requirements for the final pharmacy-to-patient segment could reduce logistical complexity and costs. By permitting this 48-hour controlled room temperature window, the update supports expanding direct-to-patient models across Europe while cutting packaging volume, weight, and overall environmental impact.

Improved Access and Patient Experience

This change is particularly valuable for patients with obesity who face stigma when collecting medication in person. Enabling discreet home delivery through online pharmacies and eHealth services is expected to improve treatment adherence and expand access to care.

Updated Labeling and Storage Rules

The revised Summary of Product Characteristics now includes the 48-hour temperature excursion allowance for the final delivery stage. The patient information leaflet remains unchanged, still advising that pens can be stored for up to 28 days below 30°C after first use. The update applies only to the injectable form of semaglutide and is based on standard pharmaceutical stability data confirming maintained product quality, safety, and efficacy.

Strategic Benefits for Obesity Care

By lowering distribution costs and simplifying logistics, this regulatory flexibility improves supply chain efficiency for high-volume GLP-1 therapies. The development, announced by Novo Nordisk, may enhance pricing flexibility, support broader patient access, and strengthen the overall value proposition of Wegovy in European health technology assessments and reimbursement decisions. It may also influence future label updates for similar therapies in the weight-management space.